Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Gardiner

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
BMC Infectious Diseases|July 21, 2012
Switch therapy in hospitalized patients with community-acquired pneumonia: tigecycline vs. levofloxacinJulio A Ramirez, Angel C Cooper, Timothy Wiemken, et al.
Journal of Virology|March 2, 2012
Tacaribe virus causes fatal infection of an ostensible reservoir host, the Jamaican fruit batAnn Cogswell-Hawkinson, Richard Bowen, Stephanie James, et al.
Plos One|June 8, 2018
An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patientsElizabeth Colston, Dennis Grasela, David Gardiner, et al.
Lasers in Surgery and Medicine|May 19, 2005
Identification of chondrocyte proliferation following laser irradiation, thermal injury, and mechanical traumaBrian J F Wong, Nidhi Pandhoh, Mai Thy Truong, et al.
BMC Infectious Diseases|November 14, 2012
A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infectionsPeter Matthews, Marc Alpert, Galia Rahav, et al.
British Journal of Clinical Pharmacology|July 21, 2021
Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plagueDung Nguyen, Jafar Sadik Shaik, Guoying Tai, et al.
Clinical Drug Investigation|August 14, 2014
The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virusTimothy Eley, Heather Sevinsky, Shu-Pang Huang, et al.
Vaccine|March 11, 2008
Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramideYaoxing Huang, Alex Chen, Xiangming Li, et al.
BMJ Open|June 23, 2017
The REAnimation Low Immune Status Markers (REALISM) project: a protocol for broad characterisation and follow-up of injury-induced immunosuppression in intensive care unit (ICU) critically ill patientsMary-Luz Rol, Fabienne Venet, Thomas Rimmele, et al.
Hepatology (Baltimore, Md.)|March 19, 2013
Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevirFiona McPhee, Dennis Hernandez, Fei Yu, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
BMC Infectious Diseases|July 21, 2012
Switch therapy in hospitalized patients with community-acquired pneumonia: tigecycline vs. levofloxacinJulio A Ramirez, Angel C Cooper, Timothy Wiemken, et al.
Journal of Virology|March 2, 2012
Tacaribe virus causes fatal infection of an ostensible reservoir host, the Jamaican fruit batAnn Cogswell-Hawkinson, Richard Bowen, Stephanie James, et al.
Plos One|June 8, 2018
An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patientsElizabeth Colston, Dennis Grasela, David Gardiner, et al.
Lasers in Surgery and Medicine|May 19, 2005
Identification of chondrocyte proliferation following laser irradiation, thermal injury, and mechanical traumaBrian J F Wong, Nidhi Pandhoh, Mai Thy Truong, et al.
BMC Infectious Diseases|November 14, 2012
A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infectionsPeter Matthews, Marc Alpert, Galia Rahav, et al.
British Journal of Clinical Pharmacology|July 21, 2021
Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plagueDung Nguyen, Jafar Sadik Shaik, Guoying Tai, et al.
Clinical Drug Investigation|August 14, 2014
The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virusTimothy Eley, Heather Sevinsky, Shu-Pang Huang, et al.
Vaccine|March 11, 2008
Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramideYaoxing Huang, Alex Chen, Xiangming Li, et al.
BMJ Open|June 23, 2017
The REAnimation Low Immune Status Markers (REALISM) project: a protocol for broad characterisation and follow-up of injury-induced immunosuppression in intensive care unit (ICU) critically ill patientsMary-Luz Rol, Fabienne Venet, Thomas Rimmele, et al.
Hepatology (Baltimore, Md.)|March 19, 2013
Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevirFiona McPhee, Dennis Hernandez, Fei Yu, et al.
Pageof 3